ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. More Details
+ 2 more risks
Limited growth with imperfect balance sheet.
Share Price & News
How has ENDRA Life Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NDRA's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: NDRA underperformed the US Medical Equipment industry which returned 19.1% over the past year.
Return vs Market: NDRA underperformed the US Market which returned 17.2% over the past year.
Price Volatility Vs. Market
How volatile is ENDRA Life Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StWhat Can We Learn About ENDRA Life Sciences' (NASDAQ:NDRA) CEO Compensation?
6 months ago | Simply Wall StHow Does Investing In ENDRA Life Sciences Inc. (NASDAQ:NDRA) Impact The Volatility Of Your Portfolio?
9 months ago | Simply Wall StInvestors Who Bought ENDRA Life Sciences (NASDAQ:NDRA) Shares A Year Ago Are Now Down 75%
Is ENDRA Life Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NDRA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NDRA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NDRA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: NDRA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NDRA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NDRA is overvalued based on its PB Ratio (12.3x) compared to the US Medical Equipment industry average (4x).
How is ENDRA Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NDRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NDRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NDRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NDRA's revenue (160.9% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: NDRA's revenue (160.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NDRA's Return on Equity is forecast to be high in 3 years time
How has ENDRA Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NDRA is currently unprofitable.
Growing Profit Margin: NDRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NDRA is unprofitable, and losses have increased over the past 5 years at a rate of 47.6% per year.
Accelerating Growth: Unable to compare NDRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NDRA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).
Return on Equity
High ROE: NDRA has a negative Return on Equity (-1478.13%), as it is currently unprofitable.
How is ENDRA Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: NDRA's short term assets ($2.3M) exceed its short term liabilities ($1.2M).
Long Term Liabilities: NDRA's short term assets ($2.3M) exceed its long term liabilities ($645.5K).
Debt to Equity History and Analysis
Debt Level: NDRA's debt to equity ratio (66.7%) is considered high.
Reducing Debt: Insufficient data to determine if NDRA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NDRA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NDRA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 44.5% each year
What is ENDRA Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NDRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NDRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NDRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NDRA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NDRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Francois Michelon (54 yo)
Mr. Francois Michelon has been the Chairman and Chief Executive Officer of ENDRA Life Sciences Inc. since July 2015 and has been its President. Mr. Michelon joined ENDRA in 2015. He has healthcare technolo ...
CEO Compensation Analysis
Compensation vs Market: Francois's total compensation ($USD978.78K) is above average for companies of similar size in the US market ($USD598.77K).
Compensation vs Earnings: Francois's compensation has increased whilst the company is unprofitable.
|CFO & Secretary||6.67yrs||US$421.75k||0.42% |
|Chief Technology Officer||13.67yrs||US$808.61k||0.94% |
|Co-Founder||no data||no data||no data|
|Human Resources Leader||3.33yrs||no data||no data|
|Chief Commercial Officer||1.33yrs||no data||no data|
Experienced Management: NDRA's management team is seasoned and experienced (5.2 years average tenure).
|Independent Director||7.67yrs||US$259.13k||1.62% |
|Independent Director||12.67yrs||US$259.13k||0.068% |
|Independent Director||5.17yrs||US$259.41k||0.19% |
|Independent Director||0.42yr||no data||0.34% |
|Scientific Advisor||5.08yrs||no data||no data|
|Scientific Advisor||no data||no data||no data|
|Scientific Advisor||0.67yr||no data||no data|
Experienced Board: NDRA's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 182.4%.
ENDRA Life Sciences Inc.'s company bio, employee growth, exchange listings and data sources
- Name: ENDRA Life Sciences Inc.
- Ticker: NDRA
- Exchange: NasdaqCM
- Founded: 2007
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$15.333m
- Shares outstanding: 20.96m
- Website: https://www.endrainc.com
Number of Employees
- ENDRA Life Sciences Inc.
- 3600 Green Court
- Suite 350
- Ann Arbor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NDRA||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jun 2017|
ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technolo ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/01 00:16|
|End of Day Share Price||2020/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.